Last week I was able first hand to see presentations in Texas on New breast cancer research incorporating the Symphony® suite of genomic tests (MammaPrint®, BluePrint® and TargetPrint®) in 10 scientific posters at the 2013 San Antonio Breast Cancer Symposium (SABCS).
“These ten studies further demonstrate Agendia’s continued commitment to providing the oncology community and their breast cancer patients with the most comprehensive and validated picture of tumor biology available in the market,” said Neil Barth, M.D., Agendia’s Chief Medical Officer.
Symphony is the only widely available test suite providing molecular subtyping -- a recent advancement in breast cancer prognosis and treatment that is highlighted in several SABCS posters. The second-generation MammaPrint test provides definitive High Risk or Low Risk information about breast cancer recurrence, with no “intermediate” results.
This new research has enhanced the way that I now make management recommendations to my new patients with breast cancer.
No comments:
Post a Comment